US Dermatologists serving on FDA advisory panels during derm drug approval: study shows half received at least 1payment from pharma; 27% > $1000, 15% >$50K, 9% > $100K. Payments from competitors outnumbered manufacturers https://t.co/bNmjkQFOJM